SENORES1,468.00

Senores Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSANOFIINNOVACAPMOREPENLABIOLCPFDCPGHLSANOFICONRORCHPHARMAMcap ₹6,760 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation16.831.3
+ Finance Costs0.024.1
+ Interest Income0.0-14.0
+ Unrealised FX (Gain) / Loss0.015.2
+ Other Non-cash Items-2.91.5
Changes in Working Capital
+ Inventories-19.3-30.3
+ Trade Receivables — Current-11.9-197.3
+ Other Financial Assets — Current-34.8-56.2
+ Other Financial Assets — Non-current-4.0-4.3
+ Other Current Assets-22.4-23.6
+ Other Non-current Assets0.03.4
+ Trade Payables — Current-45.8160.5
+ Other Financial Liabilities — Current2.7-4.7
+ Other Current Liabilities1.07.1
+ Provisions — Current0.03.5
Cash from Operating Activities
Profit Before Tax (per I/S)70.6159.1172.1
+ Total Adjustments (incl. Working Capital)-120.5-83.9
Cash from Operations (pre-tax)-50.075.3
+ Interest Received — Operating-7.20.0
+ Interest Paid — Operating-20.40.0
+ Income Taxes Paid9.213.2
Cash from Operating Activities-45.962.1
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)157.5240.1
+ Disp of Fixed Assets0.00.2
+ Acq of Investment Property0.024.6
+ Acq of Other Long-term Assets0.04.3
+ Acq of Subsidiaries / Businesses (net)3.731.9
+ Loans & Advances Repaid0.30.0
+ Payments on Futures / Forwards / Options / Swaps275.80.0
+ Interest Received — Investing7.214.0
+ Other Inflows / (Outflows) — Investing0.0166.1
Cash from Investing Activities-429.5-120.6
Cash from Financing Activities
+ Proceeds from Issue of Shares471.80.0
+ Proceeds from Other Equity Instruments0.021.7
+ Proceeds from Borrowings121.012.7
+ Repayment of Borrowings0.015.7
+ Payment of Lease Liabilities-0.71.0
+ Interest Paid20.424.1
+ Other Inflows / (Outflows) — Financing0.05.0
Cash from Financing Activities573.1-1.3
Net Changes in Cash (pre-FX)97.7-59.8
Net Changes in Cash97.7-59.8
Reference Items
EBITDA89.7168.3204.8
EBITDA Margin %22.5226.6129.60
Free Cash Flow (CFO − Capex)-203.4-178.1-178.1
Free Cash Flow to Equity-179.8
Free Cash Flow per Basic Share-44.18-38.67-38.67
Cash Flow to Net Income-0.790.51
Cash Paid for Taxes9.213.2
Cash Paid for Interest20.424.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.